Profil
Gary Woodnutt served as the Chief Scientific Officer & Senior Vice President at Lpath, Inc. from 2013 to 2016.
He also worked as the Chief Scientific Officer at Tanabe Research Laboratories U.S.A., Inc. Additionally, he is currently serving as the Senior Vice President-Translational Services at ContraFect Corp.
from 2021 to 2023.
Woodnutt received his undergraduate degree from the University of Leeds and his doctorate from The University of Reading.
Anciens postes connus de Gary Woodnutt
| Sociétés | Poste | Fin |
|---|---|---|
| CONTRAFECT CORPORATION | Corporate Officer/Principal | 04/12/2023 |
Lpath, Inc.
 Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 14/10/2016 |
Tanabe Research Laboratories U.S.A., Inc.
 Tanabe Research Laboratories U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Part of Mitsubishi Chemical Group Corp., Tanabe Research Laboratories U.S.A., Inc. develops pharmaceutical products. The company is based in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Gary Woodnutt
| The University of Reading | Doctorate Degree |
| University of Leeds | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CONTRAFECT CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
Lpath, Inc.
Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Health Technology |
Tanabe Research Laboratories U.S.A., Inc.
Tanabe Research Laboratories U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Part of Mitsubishi Chemical Group Corp., Tanabe Research Laboratories U.S.A., Inc. develops pharmaceutical products. The company is based in San Diego, CA. | Health Technology |
